Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ovaprene® in Contraceptive. The expected timing is based on the latest available company guidance and may change.
05/14/26:- Ph3 interim data detailed; enrollment completion expected in 2026, primary analysis in 2027. 08/13/26:- Positive pivotal Ph3 interim results reported. The study will continue without modification; primary analysis is expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.